They also demonstrated that IMSA101 treatment facilitated CAR T cell function through STING agonist‐induced IL‐18 secretion in mouse models of pancreatic ductal adenocarcinoma and melanoma.[106b] This study offers a mechanistic understanding of how STING agonists enhance CAR T cell activity and reinforces the potential for advancing combination therapies involving STING agonists and CAR T cells in clinical settings. The gene discussed is STING1; the disease is melanoma.